Sanara Total Liab from 2010 to 2024

SMTI Stock  USD 37.70  0.38  1.02%   
Sanara Medtech's Total Liabilities is increasing with slightly volatile movements from year to year. Total Liabilities is estimated to finish at about 30.7 M this year. Total Liabilities is the total amount of all liabilities that Sanara Medtech has, including both short-term and long-term liabilities. View All Fundamentals
 
Total Liabilities  
First Reported
2000-03-31
Previous Quarter
32 M
Current Value
49.1 M
Quarterly Volatility
M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sanara Medtech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sanara Medtech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.9 M, Interest Expense of 499.6 K or Total Revenue of 68.2 M, as well as many indicators such as Price To Sales Ratio of 4.97, Dividend Yield of 0.0324 or PTB Ratio of 7.97. Sanara financial statements analysis is a perfect complement when working with Sanara Medtech Valuation or Volatility modules.
  
Check out the analysis of Sanara Medtech Correlation against competitors.
For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide.

Latest Sanara Medtech's Total Liab Growth Pattern

Below is the plot of the Total Liab of Sanara Medtech over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Sanara Medtech's Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sanara Medtech's overall financial position and show how it may be relating to other accounts over time.
Total Liab10 Years Trend
Slightly volatile
   Total Liab   
       Timeline  

Sanara Total Liab Regression Statistics

Arithmetic Mean8,272,839
Geometric Mean5,033,782
Coefficient Of Variation118.94
Mean Deviation7,270,309
Median3,985,985
Standard Deviation9,839,542
Sample Variance96.8T
Range28.9M
R-Value0.69
Mean Square Error55.3T
R-Squared0.47
Significance0
Slope1,507,868
Total Sum of Squares1355.4T

Sanara Total Liab History

202430.7 M
202329.3 M
202219.3 M
20216.2 M
2020M
20194.7 M
20181.9 M

About Sanara Medtech Financial Statements

Investors use fundamental indicators, such as Sanara Medtech's Total Liab, to determine how well the company is positioned to perform in the future. Although Sanara Medtech's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Total Liabilities29.3 M30.7 M

Currently Active Assets on Macroaxis

When determining whether Sanara Medtech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanara Medtech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanara Medtech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanara Medtech Stock:
Check out the analysis of Sanara Medtech Correlation against competitors.
For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanara Medtech. If investors know Sanara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanara Medtech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.99)
Revenue Per Share
9.241
Quarterly Revenue Growth
0.352
Return On Assets
(0.05)
Return On Equity
(0.20)
The market value of Sanara Medtech is measured differently than its book value, which is the value of Sanara that is recorded on the company's balance sheet. Investors also form their own opinion of Sanara Medtech's value that differs from its market value or its book value, called intrinsic value, which is Sanara Medtech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanara Medtech's market value can be influenced by many factors that don't directly affect Sanara Medtech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanara Medtech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanara Medtech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanara Medtech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.